Repurposing of long-acting FDA-approved GLP-1 receptor agonists such as semaglutide, the dual GLP-1/gastric inhibitory polypeptide (GIP) receptor agonist tirzepatide, and the triple-agonist retatrutide which additionally targets glucagon receptors and is currently in clinical trials for obesity, may offer a promising strategy treating AUD
Reduced anxiety and depression, which are common comorbidities of obesity, may contribute to enhanced libido and sexual satisfaction
Others suggest that it facilitates weight loss and improves brain function
For MCAS, the goal is to modulate immune response , reduce systemic inflammation , and repair mucosal barriers that may be compromised in the gut, lungs, or skin
PS: Writing review & editing, Investigation, Writing original draft